Drug Company Under Fire After Revealing Dengue Vaccine May Harm Some

NYT, 17 December 2017
Authors: Denise Grady, Katie Thomas
“The Philippines government has begun investigations into the rollout of the immunization program by French drugmaker Sanofi, which has come under fire for discounting early warnings that its vaccine could put some people at heightened risk of a severe form of the disease.”
Find article here.

In Opioid Battle, Cherokee Want Their Day in Tribal Court

NYT, 17 December 2017
Author: Jan Hoffman
“The Cherokee suit argues that the pharmacy chains Walmart, Walgreens and CVS Health, as well as the giant drug distributors McKesson, Cardinal Health and AmerisourceBergen, flouted federal drug-monitoring laws and allowed prescription opioids to pour into the Cherokee territory at some of the highest rates in the country. Such neglect, Mr. Hembree claims, amounts to exploitation of a people.”
Find article here.

ACCC sues Voltaren makers GlaxoSmithKline and Novartis for misleading consumers

SMH, 6 December 2017
Author: Esther Han
“Two pharma giants have been taken to the Federal Court for allegedly misleading osteoarthritis sufferers into paying 33 per cent more for a “more effective” product that offers “targeted relief”, when this was not the case.”
Find article here.

Johnson & Johnson wins California lawsuit claiming asbestos in talc caused cancer

Reuters, 17 November 2017
Author: Nate Raymond
“A California jury on Thursday ruled in favor of Johnson & Johnson in a lawsuit by a woman who said she developed the cancer mesothelioma after being exposed to asbestos in the company’s talc-based products including J&J’s Baby Powder.”
Find article here.

Drug giants threaten NHS with legal action over cheaper drug that could save £84m a year

The Guardian, 1 November 2017
Author: Sarah Boseley
“Two multinational drug companies are threatening legal action to prevent patients being offered a cheap version of an effective drug against blindness which could save the NHS millions of pounds.”
Find article here.

U.S. states allege broad generic drug price-fixing collusion

Reuters, 1 November 2017
Author: Karen Freifeld
“A large group of U.S. states accused key players in the generic drug industry of a broad price-fixing conspiracy, moving on Tuesday to widen an earlier lawsuit to add many more drugmakers and medicines in an action that sent some company shares tumbling.”
Find article here.

Experts slam ‘utterly false’ claims Australians given budget flu vaccine

SMH, 30 October 2017
Author: Kate Aubusson
“Australia’s Chief Medical Officer has stridently rejected claims a “budget” flu vaccine was partly responsible for this year’s horror flu season, as the academic quoted called the reports “inaccurate”.”
Find article here.

Newly controversial opioid enforcement law under fire

The Hill, 17 October 2017
Author: Rachel Roubein
“Several lawmakers are pushing to repeal or revisit a law critics say enables the flow of deadly and addictive opioids, hours after President Trump’s drug czar nominee withdrew his name amid the controversy.”
Find article here.

California governor signs drug pricing transparency law

Reuters, 10 October 2017
Author: Bill Berkrot
“California Governor Jerry Brown on Monday signed state legislation requiring drug companies to report certain price hikes for prescription medicines in a move that could set a model for other states to follow. The law, which aims to provide more transparency around pharmaceutical and biotech company pricing methods for their medicines, requires drug manufacturers to give a 60-day notice if prices are raised more than 16 percent over a two-year period. The law also requires health plans and insurers to file annual reports outlining how drug costs affect healthcare premiums in California.”
Find article here.

U.S. judge clears way for Maryland drug price-gouging law

Reuters, 30 September 2017
Author: Deena Beasley
“A U.S. District Court judge on Friday cleared the way for Maryland to implement the nation’s first law designed to penalize drugmakers for price gouging by denying the generic drug industry trade group’s request for an injunction.”
Find article here.